## SUPPLEMENTAL MATERIAL

## Table S1. Search strategy.

- 1 Heart failure.mp or Heart Failure/
- 2 Limit 1 to (English language or humans)
- 3 Limit 2 to yr=\*2000-Current\*
- 4 Limit 3 to randomized controlled trial Limit 4 to (meta-analysis or "review" or systematic
- 5 reviews)
- 6 Limit 4 not 5

| Section            | Item             | Descriptor of PRO-specific<br>statement  | Scoring criteria   |
|--------------------|------------------|--|--|
| Title and Abstract | P1b              | PRO identified in the abstract<br>as a primary or secondary<br>outcome   | 1 point = item reported<br>0 point= item not reported  |
| Introduction       |                  |  |  |
|                    | 2a               | Relevant background and<br>rationale for why PROs were<br>assessed are described   | 1 point = item reported<br>0 point= item not reported  |
|                    | P2b              | PRO and specified PRO<br>domains hypotheses stated in<br>the background  | 1 point = if hypothesis is<br>stated and/or PRO domain<br>specified in hypothesis  |
| Methods            |                  |  |  |
|                    | P6a <sub>1</sub> | Evidence of PRO instrument<br>validity, reliability, and<br>responsiveness are cited                                     | 1 point = if evidence of PR<br>validity, reliability and<br>responsiveness was cited fo<br>at least one instrument                       |
|                    | P6a <sub>2</sub> | When or how PRO data was collected are described   | 1 point = if the method of da<br>collection (paper, telephone<br>electronic, other) and/or whe<br>PRO data was collected is<br>described |
|                    | P12a             | Statistical approaches for<br>dealing with PROs missing<br>data  | 1 point = item reported<br>0 point= item not reported  |
|                    | 13a              | Number of participants who<br>completed PROs at<br>subsequent trial phases are<br>described in the study flow<br>diagram | 1 point = item reported<br>0 point= item not reported<br>N/A = trial did not publish<br>study flow chart                                 |
| Results            |                  | olugium  |  |
|                    | 15               | Baseline PRO data are reported   | 1 point = if stated in the<br>demographics table (i.e., tab<br>1) or reported in the results<br>section                                  |
|                    | 17a              | PRO findings from one or<br>more domains and time points<br>are described with effect size<br>and precision estimate     | 1 point = if PRO findings<br>from one or several domain<br>reported with effect size an<br>precision estimate                            |

 Table S2. The Consolidated Standards of Reporting Trials (CONSORT-PRO) recommendations

 for the reporting of randomized controlled trials with patient-reported outcome (PROs).

## Discussion

| P20/21 | PRO-specific limitations, and   | 1 point = if PRO-specific       |
|--------|---------------------------------|---------------------------------|
|        | implications for the            | limitations or implications for |
|        | generalizability of study       | generalizability and/or use in  |
|        | findings and their use in       | clinical practice are discussed |
|        | clinical practice are discussed |                                 |
| 22     | PRO data are interpreted in     | 1  point = item reported        |
|        | relation to other clinical      | 0  point = item not reported    |
|        | outcomes                        |                                 |
|        |                                 | (a a (a) 7 a (a)                |

Scores ranged between zero and eleven. Table adapted from Calvert et al., (2013)<sup>7</sup> for the recommended five PRO-specific items (prefixed with the letter 'P'), selected sub-items, and modified items (e.g., P6a).

\*Primary CONSORT-PRO items were prefixed with the letter P. Selected items not denoted with the letter P were adapted from the CONSORT-2010 statement based on CONSORT-PRO group suggestions. Abbreviation: PROs, patient-reported outcomes; RCT, randomized controlled trial.